The pooled incidence of side effects of [225Ac]Ac-PSMA radioligand therapy included 63% for Grade 1 or 2 xerostomia, 14% for Grade 3 or 4 anemia, 7% for Grade 3 or 4 thrombocytopenia, and 4% for Grade 3 or 4 leukopenia, which were reported as comparable to the side effect profile of [177Lu]Lu-PSMA-617 therapy. The gene discussed is FOLH1; the disease is anemia (phenotype).